长江商报消息 ●长江商报记者 汪静 通策医疗（600763.SH）董监高出手回购。 2月24日晚间，通策医疗发布公告称，公司董事长王毅、董事黄浴华、董秘张华、财务总监徐国喜及其 他管理人员赵敏计划自2026年2月13日起6个月内增持公司股份。 根据公告，本次增持主体包括董事、总经理等高管人员，拟通过上海证券交易所系统以集中竞价方式实 施。增持金额合计不低于600万元，不超过1200万元，其中王毅、黄浴华、张华每人拟增持150万至300 万元，徐国喜拟增持50万至100万元，赵敏拟增持100万至200万元。资金来源为自有或自筹资金。 截至2月13日，上述人员已首次合计增持3.82万股，总金额约181.61万元。 长江商报记者注意到，随着千亿市值光环褪去，公司股价持续下滑，2024年4月一度跌至35.54元/股， 此后公司股价缓慢恢复增长，截至2026年2月24日，收报50.03元/股。 在2026年新年致辞中，通策医疗董事长王毅提出，"实现公司整体业绩同比增长30%"。通策医疗在此前 的调研会上表示，公司持续推进"大部制"改革，对2026年恢复稳步增长充满信心，并已正式重新提出内 部收入倍增计划。 董事和高管拟 ...

Group 1 - The core viewpoint of the article is that Tongce Medical (600763) is committed to a national expansion strategy while maintaining a steady pace, focusing on strengthening its leading position in Zhejiang province [1] - The company plans to gradually build a nationwide dental service network through a combination of mergers, acquisitions, and partnerships [1]

Core Viewpoint - Haocen Medical (002622) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Haocen Medical reported a main revenue of 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, reflecting a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -966,000 yuan, down 107.53% year-on-year [2]. - The company's debt ratio stands at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin is reported at 47.72% [2]. Stock Performance - As of February 3, 2026, Haocen Medical's stock closed at 2.98 yuan, down 1.97% with a turnover rate of 3.55% [1]. - The trading volume was 298,500 hands, with a total transaction amount of 89.67 million yuan [1]. - On February 3, the net inflow of main funds was 4.89 million yuan, accounting for 5.45% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 2.97% of the total transaction amount [1].

Core Viewpoint - Haocen Medical forecasts a total revenue of 650 million to 750 million yuan for the year 2025, indicating a significant decline in profitability due to increased market competition and rising customer acquisition costs in the dental service sector [1] Group 1: Performance Forecast - The company anticipates a revenue range of 650 million to 750 million yuan for 2025 [1] - The decline in profitability is attributed to intensified market competition and a substantial decrease in average customer spending [1] Group 2: Financial Results - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2] - The net profit attributable to shareholders was -26.41 million yuan, reflecting a year-on-year decline of 295.68% [2] - The company's gross profit margin stood at 47.72% [2] Group 3: Quarterly Performance - In Q3 2025, the company reported a single-quarter revenue of 213 million yuan, down 15.72% year-on-year [2] - The net profit attributable to shareholders for Q3 was -2.66 million yuan, a decline of 120.54% year-on-year [2] - The company’s financial expenses amounted to 31.15 million yuan for the quarter [2]

Core Viewpoint - Haocen Medical is expected to report a net profit loss of 65 million to 130 million yuan for the entire year of 2025 due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance Summary - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -0.97 million yuan, down 107.53% year-on-year [2]. - The company's debt ratio stood at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin was 47.72% [2]. Reasons for Performance Change - The decline in performance is attributed to intensified market competition, increased customer acquisition costs, and a significant drop in average customer spending in the dental medical service sector [2]. - The company plans to recognize goodwill impairment and long-term equity investment impairment based on cautious principles due to the expected recoverable amounts being lower than their book values [2].

Core Viewpoint - Haocen Medical is expected to report a loss per share of between 0.0833 yuan and 0.1666 yuan for the full year of 2025, primarily due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring items was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a year-on-year decrease of 15.72% [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -966,000 yuan, down 107.53% year-on-year [2]. Cost and Profitability - The company faced significant declines in profitability due to a substantial drop in comprehensive customer unit price [2]. - The debt ratio stood at 71.72%, indicating a high level of financial leverage [2]. - The gross profit margin was reported at 47.72%, reflecting the company's ability to maintain some level of profitability despite revenue declines [2]. Impairment and Valuation - The company plans to recognize goodwill impairment based on a cautious principle, following a goodwill impairment test [2]. - Additionally, the company will conduct impairment tests on long-term equity investments, expecting that the recoverable amounts of some investments will be lower than their book values, leading to further impairment provisions [2].

Core Viewpoint - Haocen Medical is expected to report a net profit loss of between 70 million to 140 million yuan for the full year of 2025 due to intensified market competition and increased customer acquisition costs in the dental medical service sector [1][2]. Group 1: Performance Forecast - The company anticipates a significant decline in profits for its dental medical services, attributed to a challenging market environment [2]. - The projected net profit loss for 2025 is between 70 million to 140 million yuan [1]. Group 2: Financial Performance - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders for the same period was -26.41 million yuan, a decline of 295.68% year-on-year [2]. - The company's third-quarter revenue was 213 million yuan, down 15.72% year-on-year, with a net profit of -2.66 million yuan, a decrease of 120.54% [2]. - The company reported a debt ratio of 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin stood at 47.72% [2]. Group 3: Impairment Testing - The company plans to recognize impairment losses on goodwill and long-term equity investments due to the anticipated recoverable amounts being lower than their book values [2].

Core Viewpoint - Haocen Medical (002622.SZ) is forecasting a significant loss for the fiscal year 2025, with net profit attributable to shareholders expected to be between a loss of 70 million to 140 million yuan, compared to a loss of 37.69 million yuan in the same period last year [1] Financial Performance - The company anticipates a net loss of 65 million to 130 million yuan after excluding non-recurring gains and losses, compared to a loss of 23.88 million yuan in the previous year [1] - The overall performance for 2025 is expected to be negatively impacted by increased market competition and rising customer acquisition costs in the dental service sector [1] Business Challenges - The dental service business has experienced a significant decline in profitability compared to the previous year due to intensified market competition and a substantial decrease in average customer spending [1] - The company plans to conduct impairment tests on goodwill and long-term equity investments, anticipating that some investments will have recoverable amounts lower than their book values, leading to additional impairment provisions [1]

Group 1 - The company, Haocen Medical, expects a net loss attributable to shareholders of 70 million to 140 million yuan for 2025, with basic earnings per share projected to be a loss of 0.1666 to 0.0833 yuan [1] - In the same period last year, the company reported a net loss of 37.69 million yuan, with basic earnings per share at a loss of 0.0449 yuan [1] - The significant decline in profitability is attributed to intensified market competition in the dental medical services sector, increased customer acquisition costs, and a substantial decrease in average transaction value [1] - Additionally, the company plans to recognize goodwill impairment based on a cautious approach [1]

Group 1 - The Beijing University Dental Hospital Sanya Hospital officially opened on January 10, marking it as the only national dental regional medical center in China, with a total construction area of 86,600 square meters and nine functional buildings [1][3] - The hospital is equipped with 150 dental treatment stations and 100 beds, covering all sub-specialties of dentistry, and aims to establish a benchmark brand for medical and health care in Hainan by leveraging the region's multi-dimensional advantages [1][3] - The hospital's establishment addresses the growing demand for dental health services among local residents, seasonal visitors, and international tourists in Sanya, filling the gap in high-quality dental medical services in Hainan [3] Group 2 - The strategic development of the Sanya Hospital is based on the integration of over 80 years of development from Peking University Dental Hospital and the advantages of Hainan's free trade port policies, creating a "dual-core drive" model [3] - The hospital will provide standardized services in collaboration with the Beijing headquarters, aiming to become a national regional medical center that serves Hainan, South China, and Southeast Asia [3] - Future plans include the deployment of more medical staff from the Beijing headquarters to Sanya and collaboration with Hainan Medical University for training and development of local dental professionals [3]